Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2006

View Archived Issues

Anti-AML activity of the shepherdin peptide

Novel anthrax therapy targeting host receptors

ONO-2506 active in experimental autoimmune encephalomyelitis models

Data on Sativex in multiple sclerosis patients accumulates

ZK-304709 inhibits osteolysis and tumor burden in a murine model of breast cancer bone metastasis

Preclinical efficacy of sclerostin MAbs in increasing BMD and strength in OVX rats and monkeys

ACE-011, a novel activin antagonist, improves BMD and bone architecture in OVX mice

Xanthus licenses U.S. rights to oral fludarabine

U.K. consortium to develop next-generation treatment for coronary artery disease

CrystalGenomics presents a new candidate for isoniazid-resistant strains of M. tuberculosis

UCB and Jazz expand Xyrem license agreement to include fibromyalgia syndrome

Spotlight on AR-709, Arpida's antimicrobial clinical candidate

Zevalin studied in new phase III trial for diffuse large-B-cell lymphoma

Additional data requested by MHRA for Abasol approval

Celltran and Xcellentis complete merger

Canadian clearance for second phase III study of ISA-247 in psoriasis

TorreyPines Therapeutics completes merger with Axonyx

Collegium's IND accepted for combination allergic rhinitis product

Phase II study of MTR-106 for acute migraine without aura on schedule

Anticancer compound AVE-1642 enters clinical testing

Treatment begins in second phase III trial of cangrelor in PCI

AVI-4065 results in HCV lead to protocol modification

SRT-501 safe and well tolerated in phase I studies

R&D highlights from the UBS Global Life Sciences Conference in New York: Neuromed Pharmaceuticals

Yaz approved for premenstrual dysphoric disorder

Fast track designations for talactoferrin alfa in NSCLC and diabetic foot ulcers

European approval for Suboxone for treatment of opioid dependence

FDA approves FluLaval

New Vytorin label approved

Tokyo University of Science patent discloses novel agents for preventing transplant rejection

Development of obestatin peptide derivatives reported by Leland Stanford Junior University

Recent patents impart new agents for atherosclerosis, hypertension, etc.

Inhibition of LPS synthesis by WaaC inhibitors shows promise as novel antibacterial strategy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...